Description

PT-141 Biovantage Labs Research Peptide

PT-141 (Bremelanotide) is a cyclic melanocortin receptor agonist derived from Melanotan-2, studied primarily for its MC3R and MC4R-mediated central nervous system effects on sexual arousal signalling in preclinical research models. Biovantage Labs supplies PT-141 at 99+% purity, HPLC/MS verified. Domestically fulfilled from Canada. Not for human consumption. Biovantage Labs provides this compound at 99+% purity, confirmed by batch-specific HPLC and Mass Spectrometry analysis, as a lyophilized compound for use in controlled laboratory settings.

Molecular Profile and Chemical Specifications

Primary Research Mechanisms

PT-141 research is best contextualized alongside its precursor compound Melanotan-2, which retains full MC1R/MC3R/MC4R/MC5R activity. Comparative research between the two compounds allows investigators to attribute specific research outcomes to peripheral melanogenic MC1R activity versus the central MC3R/MC4R profile that both compounds share.

Central MC4R and MC3R Activation

PT-141 activates melanocortin MC3R and MC4R receptors in hypothalamic and limbic regions associated with autonomic and motivational sexual response pathways. Research distinguishes this central mechanism from PDE5 inhibitor approaches, which act primarily via peripheral vascular mechanisms.

Dopaminergic Pathway Interactions

Research has examined PT-141’s interaction with mesolimbic dopaminergic circuits as a secondary mechanism contributing to its CNS activity profile, independent of the peripheral vasodilation that characterises alternative approaches in this research space.

Structural Relationship to Melanotan-2

PT-141 is a metabolite of Melanotan-2 formed by hydrolysis of the acetyl group. It retains MC3R and MC4R agonism but demonstrates reduced melanogenic activity relative to Melanotan-2, making it a more selective research tool for investigating central melanocortin pathways.

Central nervous system autonomic signalling research examining melanocortin pathways alongside neuropeptide-mediated smooth muscle and autonomic regulation may also reference VIP (Vasoactive Intestinal Peptide), which modulates autonomic tone through VPAC receptor-mediated mechanisms distinct from the melanocortin receptor pathways examined in PT-141 research.

Reconstitution Protocol

• Reconstitute using sterile bacteriostatic water or 0.9% sodium chloride solution
• Introduce diluent slowly along the interior vial wall do not inject directly onto the lyophilized cake
• Swirl gently until fully dissolved do not shake or vortex
• Allow the vial to equilibrate to room temperature before opening to prevent condensation

Storage and Stability

Store in a desiccated environment away from UV exposure. Avoid repeated freeze-thaw cycles, which degrade peptide chain integrity over time.

PT-141 Research FAQ

Q: How does PT-141 differ mechanistically from PDE5 inhibitors used in related research?

A: PDE5 inhibitors act by preventing cGMP degradation in smooth muscle, promoting peripheral vasodilation. PT-141 acts centrally via MC3R and MC4R in hypothalamic circuits. Research examining both mechanisms allows investigation of central versus peripheral contributions to arousal signalling.

Q: Is PT-141 for human use?

A: No. PT-141 supplied by Biovantage Labs is strictly for laboratory research purposes. It is not approved for human consumption, veterinary use, or clinical application.

Q: What purity standard does Biovantage Labs apply?

A: Every batch is verified at 99+% purity using HPLC to confirm compound concentration and Mass Spectrometry to confirm molecular identity. Batch-specific COA documentation is available upon request.

Q: Where does Biovantage Labs ship from?

A: All Biovantage Labs products are fulfilled domestically from within Canada, eliminating customs clearance risk and reducing transit time compared to international suppliers.